Press room

The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained, for the second consecutive year, the qualification "EXCELLENT" in the Profarma 2020 Plan, in recognition of its industrial activity and its commitment to development and innovation in our country.

The European Commission (EC) has approved mAbxience’s MB02 biosimilar to Avastin® (Bevacizumab), in Europe.

• The plant in Spain's Castilla-La Mancha region will undertake vial filling and packaging for AZD1222
• The company also provides drug substance manufacturing for AZD1222 through their site in Argentina
• Insud Pharma is at the forefront of Spanish companies in investment in R&D

mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America.

The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019.

The laboratory mAbxience, which is part of Insud Pharma, has inaugurated a new biosimilar monoclonal antibody plant in Garín, Buenos Aires (Argentina).

Exeltis USA, Inc. a division of the global pharmaceutical group Insud Pharma, announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Slynd™ (pronounced "slind") containing drospirenone 4 mg, an oral contraceptive tablet for pregnancy prevention.

 

•This award is recognition of the hard work and dedication of Silvia Gold, President of the Mundo Sano Foundation, in changing the course of Chagas disease.

•Mundo Sano is currently running the campaign Not a Single Baby with Chagas, to ensure that all babies and women of reproductive age have access to diagnosis and treatment.

•Chagas disease affects 8 million people worldwide. In Spain, there are estimated to be between 50,000 and 100,000 Chagas sufferers. Globally, almost 9,000 babies are born with Chagas disease every year.

Insud Pharma group have once again been rated “very good” in the 2018 edition of the Spanish government’s Profarma Programme, thanks to its industrial activity and commitment to R&D.